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Abstract
Members of the Opioid Receptor (OR) family of G protein-coupled receptors (GPCRs) are found 
throughout the peripheral and central nervous system where they play key roles in nociception and 
analgesia. Unlike the classical ORs, δ–OR, κ–OR,1 and μ-OR,2 which were delineated by 
pharmacological criteria in the 1970’s and 1980’s, the nociceptin/orphanin FQ (N/OFQ) peptide 
receptor (NOP, aka ORL-1) was discovered relatively recently via molecular cloning and 
characterization of an orphan GPCR3. Despite its high sequence similarity (~60%) with ORs, NOP 
has a strikingly distinct pharmacology4,5. Despite high sequence similarity with classical opioid G 
protein-coupled receptor subtypes, the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) 
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has a distinct biological and pharmacological role, featuring activation by the endogenous peptide 
N/OFQ, and unique selectivity for exogenous ligands. This study reports the crystal structure of 
human NOP solved in complex with the peptide mimetic antagonist Banyu Compound-24 (C-24), 
revealing atomic details of ligand-receptor recognition and selectivity. C-24 mimics the first four 
N-terminal residues of the NOP-selective peptide antagonist UFP-101, a close derivative of N/
OFQ, and provides important clues to binding of these peptides. The X-ray structure also reveals 
substantial conformational differences in the pocket regions between NOP and the “classical” 
opioid receptors κ (Ref. 1) and μ (Ref. 2), which are likely due to a small number of residues that 
vary between the two receptors. The NOP/C-24 structure explains the divergent selectivity profile 
of NOP and provides a new structural template for the design of NOP ligands.
The pharmacological effects of N/OFQ are complex and distinct from classical ORs. N/OFQ 
displays sequence similarity with other opioid peptides, notably the κ–OR endogenous 
ligand dynorphin A, but does not interact with δ–OR, κ–OR, or μ-OR. Similarly, the 
classical opioid peptides have very low affinity for NOP. Unlike the classical ORs, NOP is 
also insensitive to most morphine-like small molecules including naloxone, thereby yielding 
a pharmacologically important discriminatory feature between NOP and classical ORs. 
Studies with N/OFQ, NOP selective agonists and antagonists, and receptor or peptide 
deficient mice have shown that the NOP system has important roles in the control of central 
and peripheral functions including pain, anxiety and mood, food intake, learning and 
memory, locomotion, cough and micturition reflexes, cardiovascular homeostasis, intestinal 
motility, and immune responses6. Understanding the structural requirements for NOP ligand 
selectivity and modes of binding is therefore paramount for the optimization of future 
agonist and antagonist-based therapeutics.
By replacing the N-terminal residues of the human NOP receptor with thermostabilised 
apocytochrome b562RIL (BRIL)7 and truncating 31 C-terminal residues (see Supplementary 
Methods), we determined the 3.0 Å resolution X-ray crystal structure of this receptor in 
complex with Compound-24 (C-24), a small peptide mimetic antagonist8 (Fig. 1a). We 
found that this BRIL-NOP fusion is functional and responds to N/OFQ and the small 
molecular agonist SCH-2215109, activating endogenous Gi/o proteins in HEK 293-T cells, 
albeit with reduced potency and efficacy (Supplementary Tables 2,3), perhaps due to the C-
terminal NOP truncation. C-24 was selected for co-crystallization based on the pronounced 
thermostability it imparts on the receptor (Supplementary Fig. 1), its high affinity (IC50 = 
0.27 nM) and antagonist potency (IC50 = 0.15 nM) for NOP, and selectivity (≥ 1000-fold)8. 
Peripherally administered C-24 is able to penetrate the CNS where it antagonizes N/OFQ 
effects on nociception10 and produces beneficial responses in experimental models of 
Parkinson’s disease11. The NOP structure revealed C-24 binding deep within the orthosteric 
binding pocket (Fig. 1a) likely mimicking the “message” domain of N/OFQ (Phe1-Gly2-
Gly3-Phe4), a sequence similar to that of canonical opioid peptides (Tyr1-Gly2-Gly3-
Phe4)6,12 (Supplementary Fig. 2). Structural comparison of published GPCR crystal 
structures reveals a modularity of the 7TM core and significant variation of the extracellular 
(EC) module with boundaries defined by proline induced kinks13. NOP contains five such 
kinks in the 7TM core located at residue positions Pro1052.58, Pro1844.59, Pro2275.50, 
Pro2786.50, and Pro3167.50 (superscripts indicate residue numbers as per the Ballesteros-
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Weinstein nomenclature14), yielding repercussions on the shape of the ligand binding 
pocket. Importantly, the EC tip of helix V in NOP is shifted by more than 4 Å as compared 
with the κ–OR1 and μ-OR2 crystal structures thereby resulting in both a gap between helices 
IV and V (~12 Å between Cα of residues 184 and 215) and an expansion of the orthosteric 
pocket (Supplementary Fig. 5). However, compared with CXCR4, the EC tip of helices VI 
and VII are tilted in towards the orthosteric pocket. Unlike the κ–OR structure1, the EC half 
of helix I in NOP is pulled in towards the axis of the TM bundle in a conformation that is 
more similar to that of the chemokine receptor (PDB ID 3ODU15; Fig. 1b). This alternate 
conformation of helix I is facilitated by the presence of flexible glycine residues located at 
an apparent ‘hinge point’ that are conserved within the OR family: Gly651.46 and Gly681.49 
in NOP, and Gly731.46 and Gly761.49 inκ–OR. NOP has an additional glycine at the ‘hinge 
point’, Gly641.45, adding to the potential flexibility of this helix.
Despite low sequence conservation, extracellular loops (ECLs) 1 and 2 of NOP are 
structurally similar to those of κ–OR and CXCR4 (Fig. 1b). Specifically, the backbone of 
ECL1 in NOP is nearly indistinguishable from that of κ–OR and CXCR4. ECL2 forms an 
elongated βhairpin, which is tethered to the EC tip of helix III by a structurally conserved 
disulfide bond between Cys1233.25 and Cys200ECL2. This β-hairpin motif is also observed in 
κ–OR and CXCR4, suggesting a common structural motif of the γ-branch16 Class A peptide 
binding receptors. Unlike δ–OR and μ-OR, the ECL2s of κ–OR and NOP are enriched in 
aspartate and glutamate residues making the loop and the entrance to their binding pocket 
very acidic (Supplementary Fig. 6). Moreover, ECL2 in NOP is two residues shorter than in 
κ–OR, making it and differences in charge distribution possible determinants for selectivity. 
These details are consistent with N/OFQ / dynorphin A chimera peptide data showing that 
replacement of as few as six residues on N/OFQ with the corresponding residues from 
dynorphin A dramatically impaired affinity and activity towards NOP17.
The intracellular loop (ICL) 2 of NOP receptor ‘B’ forms a short α-helix, which has been 
observed in a number of other GPCRs; and ICL3 of NOP receptor ‘A’ is structured and 
connects helices V and VI allowing this region to extend into the cytoplasm for interaction 
with heterotrimeric Gi/Go proteins (Fig. 1c). Structural alignment with thermostabilized 
A2AAR18 (PDB ID 3PWH) reveals a similar orientation of helices V and VI, although the 
helices are shorter in the NOP structure (Fig. 1c, Supplementary Fig. 7). The loop regions of 
these ICL3s are conformationally dissimilar, and differ in length by seven residues (8 
residues long in A2AAR versus 15 residues in NOP). Both ICL2 and ICL3 are tethered to the 
7TM core, restricting their mobility, through interactions involving arginine residues that are 
conserved within the OR family: Arg162ICL2 forms a salt bridge with Asp1473.49 to the 
conserved D(E)RY motif, and Arg2596.31 forms a hydrogen bond with the backbone 
carbonyl with Val245ICL3 (Supplementary Fig. 7).
The NOP/C-24 structure highlights specific residues in the pocket essential for N/OFQ 
binding and receptor subtype selectivity (Fig. 2). The orthosteric binding pocket of NOP is 
relatively large, reflecting its ability to bind large endogenous peptides. With a similar pose 
in both NOP molecules (RMSD = 0.6 Å), C-24 interacts with the ‘floor’ of the pocket 
through several hydrophobic and electrostatic interactions. Mutagenesis of the NOP’s 
binding pocket defined the relative impact of specific residues on C-24 and N/OFQ binding 
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and function (Supplementary Tables 4,5). The protonated nitrogen of the C-24 piperidine 
ring forms a crucial salt bridge with Asp1303.32, a residue that is conserved in the OR family 
and all biogenic amine GPCRs. Mutations of Asp1303.32 to either alanine or asparagine 
abrogate N/OFQ binding, highlighting the requirement of the negative charge at this 
position19 (Fig. 2 and Supplementary Tables 4,5). Numerous studies have proposed that 
Asp1303.32 is involved in a salt bridge interaction with the positively charged N-terminal 
nitrogen of N/OFQ 20,21. In addition to the anchoring salt bridge between Asp1303.32 and 
the amino moiety of C-24, the linked benzofuran/piperidine rings are buried in a 
hydrophobic pocket created by residues from helices III, V and VI. The benzofuran ‘head’ 
group is sandwiched between Met1343.36 and Tyr1313.33, where the Met3.36 side chain 
adopts a different, more buried rotamer as compared to κ–OR, thereby allowing a deeper 
penetration of the C-24 ring system. This is further emphasized by the modest effect of a 
Met1343.36Ala mutation on the potency of NOP ligands (Supplementary Tables 4,5). A 
Tyr1313.33Phemutation had no effect on agonist binding while Tyr1313.33Ala was 
deleterious (Supplementary Tables 4,5) suggesting that Tyr131 participates in π-stacking 
interactions with Phe1 of the peptide19.
At the ‘tail’ end of C-24, the carbonyl group adjacent to the pyrrolidine ring is hydrogen 
bonded to Gln1072.60, a residue stabilized by a hydrogen bond to Tyr3097.43. While a 
Gln1072.60Ala mutation results in a 10-fold loss in C-24 binding and over 300-fold 
reduction in N/OFQ potency, mutation of Tyr3097.43 abolishes binding of C-24 and reduces 
N/OFQ potency ~7-fold (Supplementary Tables 4–5). Interestingly, both Gln2.60 and Tyr7.43 
are present in the κ–OR structure, albeit in very different conformations (Supplementary 
Fig. 8).
The crystal structure of NOP in complex with C-24 afforded us a unique opportunity to 
elucidate the molecular basis for both the high affinity binding by N/OFQ derived peptide 
antagonists and their pronounced subtype selectivities (Fig. 3). Importantly, we verified that 
the C-24 binding mode can be reliably reproduced by energy-based docking of C-24 to the 
NOP receptor with an RMSD ~ 0.9 Å. Moreover, docking of another piperidine derivative, 
Compound-35 (C-35)22, closely mimics the binding of C-24, while docking a less active 
stereoisomer Compound-3622 yields a significantly distorted binding pose in the pyrrolidine 
region and a reduced binding score (not shown). Previously, Trapella et al.22 proposed that 
C-24 mimics the N-terminal four residues of N/OFQ related peptide antagonists [Nphe1]N/
OFQ(1-–3)-NH2 (ref 23) and UFP-101 (ref 24). Automated docking of the four N-terminal 
residues of UFP-101 results in a conformation of the Nphe1-Gly2-Gly3-Phe4 tetrapeptide 
where the Nphe1 and Phe4 rings of the peptide make the same hydrophobic interactions as 
the aromatic rings of C-24, and the N-terminal amino group forms a salt bridge with 
Asp1303.32, thus supporting the proposed similarity in the binding poses between small 
molecules and peptide analogues (Fig. 3c).
The “address” domain of N/OFQ (residues 5–17) was previously shown by NMR to have a 
strong preference for α-helical secondary structure25,26, which is likely preserved in 
UFP-101 since the only difference in this domain are the mutations Leu14Arg and 
Ala15Lys. Docking of the full-length UFP-101 suggests a plausible fit of the α-helical 
address domain into the binding pocket entrance shaped by the highly acidic tip of ECL2 
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and helices II and VII, with all six basic residues of the peptide forming ionic interactions 
with acidic side chains of NOP (Fig. 3c,d,e).
Interactions of the “address” domain of N/OFQ(1–13) with helices II (residues 107–113)27 
and VII (residues 296–302)19 were previously demonstrated by photocrosslinking, a finding 
consistent with our mutagenesis data showing the crucial importance of Asp1102.63 in 
binding of N/OFQ but not small molecule antagonists or the agonist SCH-221510 
(Supplementary Table 5). These results suggest a similar binding mode for the “address” 
domains of N/OFQ-derived peptides. On the other hand, note that the κ–OR -binding 
peptide dynorphin A has a Pro10 in the middle of the “address” sequence12 which is 
unfavorable for α-helix formation, suggesting potential differences in the binding mode for 
this “classical” opioid peptide.
As mentioned above, the NOP displays dramatically reduced affinities for both morphine-
based small molecules and the classical OR peptide ligands: N/OFQ contains an N-terminal 
FGGF instead of the YGGF motif found in the classical OR peptide ligands. Previous 
biochemical studies attributed this distinct selectivity profile to the three residue positions in 
the binding pocket of NOP that differ from all other ORs: Ala2165.39 (Lys in others), 
Gln2806.52 (His in others) and Thr3057.39 (Ile in others). Mutation of these three positions 
on the N/OFQ receptor to classical OR residues has been shown to be sufficient for 
conferring high affinity binding to a dynorphin-derived κ–OR selective peptide28,29. 
Moreover, the same three mutations conferred nM-range NOP binding of morphine-based 
opioid antagonists such as bremazocine, naltrexone and naltrindole, as well as a κ–OR 
specific antagonist nor-BNI29. The crystal structures of NOP and κ–OR reveal that the side 
chains of these three residues are pointing towards the interior of the binding pocket (Fig. 4, 
Supplementary Fig. 8). In NOP, Gln2806.52 and Thr3057.39 are involved in C-24 
interactions, while all three of the cognate residues at these positions are involved in κ–OR 
interactions with JDTic and with the modeled nor-BNI antagonists1. Interestingly, while 
most of the modified side chains are polar, none form direct hydrogen bonding interactions 
to the ligands tested, so that the selectivity profiles cannot be explained by simple polar-to-
hydrophobic (or vice versa) changes of ligand contacts. Instead, a comparison of the NOP 
and κ–OR structures reveals that several of the NOP-specific side chain changes, including 
two of the substitutions mentioned above (Ala5.39Lys, Gln6.52His), are involved in a large-
scale reshaping of the binding pocket and an alternate coordination of water molecules (Fig. 
4). Located closer to the ligand binding pocket entrance, Lys2275.39 in κ–OR, and 
potentially in other classical ORs, is involved in salt bridges with the side-chains of 
Asp2235.35 and Glu2976.58 (Fig. 4a). Replacement of Lys5.39 to alanine in NOP precludes 
these stabilizing ionic interactions and is accompanied by an outward shift of the EC half of 
helix V in the NOP crystal structure, and an inward shift of helix VI. OR subtype alteration 
of the large Lys5.39 side chain and the accompanying shifts of the α-helices significantly 
reshape the entrance to the pocket, which likely impacts the binding of “address” domains of 
peptides and synthetic ligands.
The κ–OR structure reveals a cluster of water molecules that is coordinated by two of the 
classical OR specific residues involved in binding pocket remodeling (Fig. 4b), His2916.52 
and the backbone carbonyl of Lys2275.39. Interestingly, one such tightly bound water 
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molecule is coordinated by His6.52 and appears to preclude a buried rotamer conformation of 
Met3.36 in κ–OR which is observed in NOP, resulting in a deviation of more than 6 Å 
between the Cε atoms of the side chain in these two crystal structures (Fig 4c). This Met3.36 
residue is conserved in all ORs and makes extensive hydrophobic interactions with the 
corresponding ligands in both NOP and κ–OR. As a consequence, the 7-
hydroxyisoquinoline ‘head-group’ of κ–OR’s ligand, JDTic, is not able to penetrate deeply 
into this area of the orthosteric pocket as compared with the benzofuran group of C-24. The 
‘reoriented’ hydroxylated head-group of JDTic is stabilized by a hydrogen bond interaction 
to a water molecule that is coordinated by the backbone carbonyl of Lys2275.39, potentially 
explaining the need for a tyrosine residue at the N-terminus of dynorphin A. With 
modifications of Lys5.39 to Ala5.39 and His6.52 to Gln6.52 in the NOP receptor, remodeling of 
the binding pocket that includes backbone shift in helix V, repacking of the Met3.36 side 
chain and water rearrangements provide a likely explanation for selectivity in the “message” 
domain of the peptide ligands.
Perhaps most intriguing are the evolutionary differences between NOP and the other three 
classical opioid receptors (κ–OR, μ-OR, δ–OR). Despite high sequence identity between 
receptors, dramatic differences in ligand selectivity between these ORs go in hand with 
substantial changes in the structure of their binding pockets. This situation is very different 
from other GPCR subfamilies (e.g. β adrenergic, muscarinic) where different subtypes signal 
via the same ligands via highly conserved orthosteric pocket architectures. With structural 
data forκ–OR1, μ-OR2, and NOP now available, and the fourth (δ–OR) opioid receptor 
structure likely to come in the near future, one can begin to investigate the ligand structure 
activity relationships and evolutionary aspects of this receptor subfamily in greater detail.
Methods Summary
BRIL-NOP was expressed in Spodoptera frugiperda (Sf9) insect cells. Ligand binding asays 
were performed as described in Methods online. Sf9 membranes were solubilized using 
0.5% n-dodecyl-β-D-maltopyranoside (w/v) and 0.1% cholesteryl hemisuccinate (w/v), and 
purified by immobilized metal ion affinity chromatography (IMAC). Receptor 
crystallization was performed by the lipidic cubic phase (LCP) method. The protein-LCP 
mixture contained 40% (w/w) concentrated receptor solution, 54% (w/w) monoolein, and 
6% (w/w) cholesterol. Crystals were grown in 40 nL protein-laden LCP bolus overlaid by 
0.8 μL of precipitant solution (25–30% (v/v) PEG 400, 100–200 mM potassium sodium 
tartrate tetrahydrate, 100 mM BIS-TRIS propane [pH 6.4]) at 20 °C. Crystals were harvested 
directly from LCP matrix and flash frozen in liquid nitrogen. X-ray diffraction data were 
collected at 100 K on the 23ID-B/D beamline (GM/CA CAT) of the Advanced Photon 
Source at the Argonne National Laboratory using a 10 μm collimated minibeam. Diffraction 
data from 23 crystals were merged for the final dataset. Data collection, processing, 
structure solution and refinement are described in Methods online.
Full Methods and any associated references are available in the online version of the paper 
at (web).
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Figure 1. Structural overview of the NOP receptor
(a) Structural overview of NOP colored gray and ECL2 colored red. The bound ligand C-24 
is depicted as green sticks, and transparent disks highlight the EC and IC membrane 
boundaries (colored blue and red, respectively). (b) Structural superposition of NOP 
molecules ‘A’ and ‘B’, κ–OR1 (PDB ID 4DJH), and CXCR415 (PDB ID 3ODU) colored 
gray, yellow, blue and orange, respectively. Compared with κ–OR, the EC portion of helix I 
from NOP is tilted inward towards the orthosteric pocket in a conformation that is similar to 
CXCR4. (c) Structural superposition of NOP molecules ‘A’ and ‘B’ and thermostabilized 
A2AAR18 (PDB ID 3PWH) colored gray, yellow, and green, respectively, highlighting 
conformational differences between the ICLs.
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Figure 2. The orthosteric ligand binding pocket
(a) Cartoon representation of NOP with its large orthosteric ligand binding pocket shown as 
a blue transparent surface. ECL2 is colored red in all subsequent figures. (b) Extracellular 
view of the pocket with bound C-24 depicted as green sticks. (c) Side view of C-24 in the 
binding pocket with yellow dashed lines highlighting hydrogen bonding interactions and salt 
bridges. (d) Sigma-A weighted 2|mFo|-|DFc| electron density map contoured at 1.0 σ 
(0.0173 e/ Å 3) around C-24 inside the ligand binding pocket. (e) Schematic representation 
of C-24 interactions with NOP (B) with labeled distances (Å). Residue labels are colored 
according to the effect on C-24 binding when replaced with alanine: Magenta labels on 
black background abolish C-24 binding; red labels result in ~10-fold decrease in affinity; 
green labeled residues slightly increase the affinity of C-24, blue labeled residues were not 
tested, and Asp110 had no effect on the binding of C-24, although it is crucial for N/OFQ 
binding.
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Figure 3. Molecular docking in the orthosteric binding pocket
Docking of C-24 (a), its analog C-35 (b), and peptide antagonist UFP-101 (c, d, e) in the 
NOP. The crystallographic pose of C-24 is green in all panels, and the docked molecules 
(C-24, C-35, UFP-101) are colored yellow. The Nphe1-Gly2-Gly3-Phe4 tetrapeptide portion 
of the docked UFP-101 is depicted as sticks, and the “address” domain (residues 5–17) of 
this peptide is represented as a cartoon. Panel (c) shows a ‘sliced’ side-view of the pocket; 
panel (d) shows a view from the extracellular surface; and panel (e) shows the electrostatic 
surface potentials of the UFP-101 peptide colored blue to red, corresponding to positive and 
negative surface potentials (+3 to −3 kT/e), respectively. ECL2 is colored red, and the acidic 
Asp and Glu residues from the ECL2 β-hairpin are depicted as red sticks.
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Figure 4. Conformational differences in the ligand binding pocket between NOP/C-24 and κ–
OR/JDTic
(a) ‘Sliced’ surface representation of NOP highlighting the deep binding pocket bound with 
C-24 (colored green) and JDTic (colored magenta) from the superimposed κ–OR structure. 
(b) (c) Different views of NOP (colored gray with green C-24) superimposed with the κ–OR 
structure1 (PDB ID 4DJH; colored blue with magenta JDTic). Hydrogen bonding 
interactions are depicted as dashed yellow and black lines for NOP and κ–OR, respectively. 
The waters from the κ–OR structure are depicted as cyan spheres. Residue labels are colored 
black and blue for NOP and κ–OR, respectively. Panel (a) highlights the conformational 
shifts observed between helices V and VI that result in differential binding pocket 
architectures. Panel (b) highlights the alternate rotamer of Met3.36 (134 in NOP & 142 in κ–
OR) in the pocket which affects the orientation of the ligand’s head groups.
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